Anita Mehta
Internal Medicine · Bismarck, NDNPI 1740799600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.
Across 60 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$234
- AbbVie$130
- Lilly USA, LLC$86
- Novo Nordisk$85
- E.r. Squibb & Sons, L.L.C.$60
- Pfizer$60
- plus $366 from 12 others
What the payments were for
- Food & beverage$1,021100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $234 |
| AbbVie | 6 | $130 |
| Lilly USA, LLC | 6 | $86 |
| Novo Nordisk | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Pfizer | 4 | $60 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Novartis | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 3 | $44 |
| AstraZeneca | 2 | $36 |
| Abbott | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Boehringer Ingelheim | 2 | $26 |
| Medtronic | 1 | $21 |
| Biogen | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| GSK | 1 | $18 |
How this compares
$1,021 in reported general payments places this provider in the 85th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 105 | $115,556 |
| JardianceEmpagliflozin | 109 | $110,481 |
| EliquisApixaban | 76 | $86,548 |
| FarxigaDapagliflozin Propanediol | 74 | $57,633 |
| OzempicSemaglutide | 39 | $39,572 |
| XareltoRivaroxaban | 29 | $19,894 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $17,449 |
| JanuviaSitagliptin Phosphate | 18 | $13,990 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $13,464 |
| MyrbetriqMirabegron | 15 | $8,923 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,581 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,550 |
| EntrestoSacubitril/Valsartan | 11 | $7,131 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,031 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 23 | $6,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $26 | $118,062123 claims |
| Lilly USA, LLCMounjaro | $86 | $115,556105 claims |
| PfizerEliquis, Abrysvo | $60 | $93,38799 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $36 | $64,66585 claims |
| Novo NordiskOzempic | $85 | $39,57239 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $18 | $23,95827 claims |
| NovartisEntresto | $45 | $7,13111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Bismarck
- Khalin DendyBismarck$10K
- Stephanie CanhamBismarck$4K
- Radu RautaBismarck$3K
- Donald GrenzBismarck$3K
- Julia SchwartzBismarck$3K
- Amanda BlanchardBismarck$3K
- Ramtin RamseyBismarck$958
- Michael LuckenbillBismarck$910
- Sean AllojuBismarck$843
- Khris RamdeenBismarck$612
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.